{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:01:01Z","timestamp":1791054061175,"version":"4.1.0"},"reference-count":208,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T00:00:00Z","timestamp":1634601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Thyroid cancer is ranked in ninth place among all the newly diagnosed cancer cases in 2020. Differentiated thyroid cancer behavior can vary from indolent to extremely aggressive. Currently, predictions of cancer prognosis are mainly based on clinicopathological features, which are direct consequences of cell and tissue microenvironment alterations. These alterations include genetic changes, cell cycle disorders, estrogen receptor expression abnormalities, enhanced epithelial-mesenchymal transition, extracellular matrix degradation, increased hypoxia, and consecutive neovascularization. All these processes are represented by specific genetic and molecular markers, which can further predict thyroid cancer development, progression, and prognosis. In conclusion, evaluation of cancer genetic and molecular patterns, in addition to clinicopathological features, can contribute to the identification of patients with a potentially worse prognosis. It is essential since it plays a crucial role in decision-making regarding initial surgery, postoperative treatment, and follow-up. To date, there is a large diversity in methodologies used in different studies, frequently leading to contradictory results. To evaluate the true significance of predictive markers, more comparable studies should be conducted.<\/jats:p>","DOI":"10.3390\/medicina57101131","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T03:01:13Z","timestamp":1634698873000},"page":"1131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Can We Predict Differentiated Thyroid Cancer Behavior? Role of Genetic and Molecular Markers"],"prefix":"10.3390","volume":"57","author":[{"given":"Rita","family":"Niciporuka","sequence":"first","affiliation":[{"name":"Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia"},{"name":"Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurijs","family":"Nazarovs","sequence":"additional","affiliation":[{"name":"Department of Pathology, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturs","family":"Ozolins","sequence":"additional","affiliation":[{"name":"Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia"},{"name":"Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-7722","authenticated-orcid":false,"given":"Zenons","family":"Narbuts","sequence":"additional","affiliation":[{"name":"Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia"},{"name":"Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvins","family":"Miklasevics","sequence":"additional","affiliation":[{"name":"Institute of Oncology, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janis","family":"Gardovskis","sequence":"additional","affiliation":[{"name":"Department of Surgery, Riga Stradins University, Pilsonu Street 13, LV-1002 Riga, Latvia"},{"name":"Department of Surgery, Pauls Stradins Clinical University Hospital, Pilsonu Street 13, LV-1002 Riga, Latvia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"ref_1","unstructured":"Thyroid\u2014Global cancer observatory. Available online: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/32-Thyroid-fact-sheet.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0140-6736(03)12488-9","article-title":"Thyroid carcinoma","volume":"361","author":"Sherma","year":"2003","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"R499","DOI":"10.1530\/ERC-16-0372","article-title":"Application of molecular biology of differentiated thyroid cancer for clinical prognostication","volume":"23","author":"Marotta","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nrc3431","article-title":"Molecular pathogenesis and mechanisms of thyroid cancer","volume":"13","author":"Xing","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hu, J., Yuan, I., Mirshahidi, S., Simental, A., Lee, S., and Yuan, X. (2021). Thyroid carcinoma: Phenotypic features, underlying biology and potential relevance for targeting therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041950"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Toraih, E., Hussein, M., Zerfaoui, M., Attia, A., Ellythy, A.M., Mostafa, A., Ruiz, E., Shama, M., Russell, J., and Randolph, G. (2021). Site-specific metastasis and survival in papillary thyroid cancer: The importance of brain and multi-organ disease. Cancers, 13.","DOI":"10.3390\/cancers13071625"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0002-9343(94)90321-2","article-title":"Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer","volume":"97","author":"Mazzaferri","year":"1994","journal-title":"Am. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.30699\/ijp.13.2.125","article-title":"A review of driver genetic alterations in thyroid cancers","volume":"13","author":"Khatami","year":"2018","journal-title":"Iran. J. Pathol."},{"key":"ref_10","unstructured":"Consortium TAPG (2017). AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov., 7, 818\u2013831."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1210\/jc.2012-2104","article-title":"BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: A meta-analysis","volume":"97","author":"Li","year":"2012","journal-title":"J. Clin. Endocrinol. Metabolism"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1159\/000443032","article-title":"Meta-analyses of association between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinoma","volume":"38","author":"Zhang","year":"2016","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-016-0979-1","article-title":"Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: A meta-analysis","volume":"14","author":"Liu","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1002\/cncr.26500","article-title":"The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer","volume":"118","author":"Kim","year":"2011","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MD.0b013e31826a9c71","article-title":"BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment","volume":"91","author":"Tufano","year":"2012","journal-title":"Medicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.7150\/jca.33105","article-title":"The BRAFV600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancer","volume":"11","author":"Ge","year":"2020","journal-title":"J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAFV600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.anl.2011.07.011","article-title":"BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma","volume":"39","author":"Ahn","year":"2012","journal-title":"Auris Nasus Larynx"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1530\/EC-19-0246","article-title":"Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma","volume":"1","author":"Yan","year":"2019","journal-title":"Endocr. Connect."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Li, X., and Kwon, H. (2020). The Impact of BRAF mutation on the recurrence of papillary thyroid carcinoma: A meta-analysis. Cancers, 12.","DOI":"10.3390\/cancers12082056"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1530\/ERC-14-0531","article-title":"BRAFV600E mutation in papillary thyroid microcarcinoma: A meta-analysis","volume":"22","author":"Li","year":"2015","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_22","first-page":"591","article-title":"BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis","volume":"35","author":"Ma","year":"2015","journal-title":"Acta Acad. Med. Wuhan"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1089\/thy.2015.0391","article-title":"BRAFV600E is correlated with recurrence of papillary thyroid microcarcinoma: A systematic review, multi-institutional primary data analysis, and meta-analysis","volume":"26","author":"Chen","year":"2016","journal-title":"Thyroid"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/OTT.S101800","article-title":"Diagnostic value of BRAFV600E-mutation analysis in fine-needle aspiration of thyroid nodules: A meta-analysis","volume":"9","author":"Teng","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1159\/000333274","article-title":"BRAF mutation testing of thyroid fine-needle aspiration specimens enhances the predictability of malignancy in thyroid follicular lesions of undetermined significance","volume":"55","author":"Adeniran","year":"2011","journal-title":"Acta Cytol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/cen.12806","article-title":"BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: A systematic review and meta-analysis","volume":"84","author":"Trimboli","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.1073\/pnas.85.18.6622","article-title":"A highly conserved repetitive DNA sequence, (TTAGGG)n, present at the telomeres of human chromosomes","volume":"85","author":"Moyzis","year":"1988","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","first-page":"569","article-title":"Structure and function of telomeres","volume":"350","author":"Blackburn","year":"1991","journal-title":"Nat. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12020-019-02117-2","article-title":"Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: A systematic review and meta-analysis","volume":"67","author":"Yang","year":"2019","journal-title":"Endocrine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1010428317713913","DOI":"10.1177\/1010428317713913","article-title":"Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations\u2014a meta-analysis","volume":"39","author":"Vuong","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1507\/endocrj.EJ20-0063","article-title":"BRAF and TERT promoter mutations: Clinical application in thyroid cancer","volume":"67","author":"Chung","year":"2020","journal-title":"Endocr. J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-15-0533","article-title":"TERT promoter mutations in thyroid cancer","volume":"23","author":"Liu","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"36990","DOI":"10.1038\/srep36990","article-title":"TERT promoter mutation and its association with clinicopathological features and prognosis of papillary thyroid cancer: A meta-analysis","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e11548","DOI":"10.1097\/MD.0000000000011548","article-title":"The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer","volume":"97","author":"Jin","year":"2018","journal-title":"Medicine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"540238","DOI":"10.3389\/fonc.2020.540238","article-title":"The coexistence of genetic mutations in thyroid carcinoma predicts histopathological factors associated with a poor prognosis: A systematic review and network meta-analysis","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13000-019-0849-6","article-title":"Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China","volume":"14","author":"Huang","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1530\/ERC-14-0359","article-title":"Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy","volume":"21","author":"Liu","year":"2014","journal-title":"Endocr. Related Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1530\/EC-17-0010","article-title":"A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma","volume":"6","author":"Vuong","year":"2017","journal-title":"Endocr. Connect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1634\/theoncologist.2013-0072","article-title":"RAS mutations in thyroid cancer","volume":"18","author":"Howell","year":"2013","journal-title":"Oncologist"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/thy.2014.0241","article-title":"Prognostic value of genetic mutations in thyroid cancer: A meta-analysis","volume":"25","author":"Pak","year":"2015","journal-title":"Thyroid"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E914","DOI":"10.1210\/jc.2012-3396","article-title":"RAS mutations in thyroid FNA specimens are highly predictive of predominantly low-risk follicular-pattern cancers","volume":"98","author":"Gupta","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"P\u00f3voa, A., Teixeira, E., Bella-Cueto, M., Batista, R., Pestana, A., Melo, M., Alves, T., Pinto, M., Sobrinho-Sim\u00f5es, M., and Maciel, J. (2021). Genetic determinants for prediction of outcome of patients with papillary thyroid carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13092048"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-016-0559-9","article-title":"Clinical utility of RAS mutations in thyroid cancer: A blurred picture now emerging clearer","volume":"14","author":"Xing","year":"2016","journal-title":"BMC Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fendo.2012.00054","article-title":"RET\/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma","volume":"3","author":"Romei","year":"2012","journal-title":"Front. Endocrinol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/EP:13:1:03","article-title":"RET\/PTC rearrangement in thyroid tumors","volume":"13","author":"Nikiforov","year":"2002","journal-title":"Endocr. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Agrawal","year":"2014","journal-title":"Cell"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Sisdelli, L., Cordioli, M., Vaisman, F., Caria, P., Mai, S., and Cerutti, J. (2020). Genetic landscape of papillary thyroid carcinoma and nuclear architecture: An overview comparing pediatric and adult populations. Cancers, 12.","DOI":"10.3390\/cancers12113146"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Yoo, S.-K., Lee, S., Kim, S.-J., Jee, H.-G., Kim, B.-A., Cho, H., Song, Y.S., Cho, S.W., Won, J.-K., and Shin, J.-Y. (2016). Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers. PLoS Genet., 12.","DOI":"10.1371\/journal.pgen.1006239"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3803\/EnM.2019.34.1.1","article-title":"Genomic characterization of differentiated thyroid carcinoma","volume":"34","author":"Song","year":"2019","journal-title":"Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.neo.7900101","article-title":"Cell cycle and apoptosis","volume":"2","author":"Pucci","year":"2000","journal-title":"Neoplasia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.133.4.1710","article-title":"Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67","volume":"133","author":"Gerdes","year":"1984","journal-title":"J. Immunol."},{"key":"ref_52","unstructured":"McManus, L.M., and Mitchell, R.N. (2014). Pathobiology of Human Disease: A Dynamic Encyclopedia of Disease Mechanisms, Academic Press."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1507\/endocrj.EJ14-0293","article-title":"Prognostic classification of thyroid follicular cell tumors using Ki-67 labeling index: Risk stratification of thyroid follicular cell carcinomas [Review]","volume":"62","author":"Kakudo","year":"2015","journal-title":"Endocr. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1007\/s00268-010-0746-3","article-title":"Prognostic significance of Ki-67 labeling index in papillary thyroid carcinoma","volume":"34","author":"Ito","year":"2010","journal-title":"World J. Surg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.7314\/APJCP.2015.16.4.1605","article-title":"Expression of Ki67 in papillary thyroid microcarcinoma and its clinical significance","volume":"16","author":"Zhou","year":"2015","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-018-1384-8","article-title":"The clinicopathological significance of Ki67 in papillary thyroid carcinoma: A suitable indicator?","volume":"16","author":"Tang","year":"2018","journal-title":"World J. Surg. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12253-012-9565-1","article-title":"Significance of AgNORs and Ki-67 proliferative markers in differential diagnosis of thyroid lesions","volume":"19","author":"Aiad","year":"2013","journal-title":"Pathol. Oncol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.anndiagpath.2010.11.005","article-title":"Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high\u2013molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma","volume":"15","author":"Tan","year":"2011","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000347148","article-title":"Ki-67 labeling index is a predictor of postoperative persistent disease and cancer growth and a prognostic indicator in papillary thyroid carcinoma","volume":"2","author":"Miyauchi","year":"2013","journal-title":"Eur. Thyroid. J."},{"key":"ref_60","first-page":"55","article-title":"The association between lymph node metastasis and molecular markers in differentiated thyroid cancer","volume":"14","author":"Sak","year":"2018","journal-title":"Acta Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.2147\/OTT.S135593","article-title":"The diagnostic and prognostic values of Ki-67\/MIB-1 expression in thyroid cancer: A meta-analysis with 6,051 cases","volume":"10","author":"Pan","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"41752","DOI":"10.1038\/srep41752","article-title":"TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: Combination of two independent factors","volume":"7","author":"Matsuse","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.14639\/0392-100X-N0311","article-title":"Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma","volume":"40","author":"Viana","year":"2020","journal-title":"Acta Otorhinolaryngol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12020-018-1627-z","article-title":"High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma","volume":"61","author":"Mu","year":"2018","journal-title":"Endocrine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.dnarep.2018.07.008","article-title":"Multiple functions of p27 in cell cycle, apoptosis, epigenetic modification and transcriptional regulation for the control of cell growth: A double-edged sword protein","volume":"69","author":"Abbastabar","year":"2018","journal-title":"DNA Repair"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1038\/onc.2011.9","article-title":"Cytoplasmic p27 is oncogenic and cooperates with RAS both In Vivo and In Vitro","volume":"30","author":"Serres","year":"2011","journal-title":"Oncogene"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrc2347","article-title":"The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy","volume":"8","author":"Chu","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I","article-title":"Regulation of the Cdk inhibitor p27 and its deregulation in cancer","volume":"183","author":"Slingerland","year":"2000","journal-title":"J. Cell Physiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3455","DOI":"10.4161\/cc.8.21.9789","article-title":"p27 as jekyll and hyde: Regulation of cell cycle and cell motility","volume":"8","author":"Larrea","year":"2009","journal-title":"Cell Cycle"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/nrc1501","article-title":"Regulation of the cytoskeleton: An oncogenic function for cdk inhibitors?","volume":"4","author":"Besson","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/0008-5472.CAN-19-3663","article-title":"p27 as a transcriptional regulator: New roles in development and cancer","volume":"80","author":"Razavipour","year":"2020","journal-title":"Cancer Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PAI.0b013e318228de00","article-title":"Value of immunohistochemical expression of p27 and galectin-3 in differentiation between follicular adenoma and follicular carcinoma","volume":"20","author":"Abulkheir","year":"2012","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/PAI.0b013e31829b05db","article-title":"Prognostic value of p27 in follicular thyroid carcinoma and its relation to radioactive iodine response","volume":"22","author":"Kotb","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5301\/jbm.5000239","article-title":"Clinicopathological significance of loss of p27Kip1 expression in papillary thyroid carcinoma","volume":"32","author":"Kim","year":"2017","journal-title":"Int. J. Biol. Markers"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.mpdhp.2020.02.004","article-title":"Molecular biology meets the endocrine pathologist: An appraisal of p27 in thyroid malignancy","volume":"26","author":"Smith","year":"2020","journal-title":"Diagn. Histopathol."},{"key":"ref_76","first-page":"15","article-title":"Cyclin D1, RET and p27 expression in papillary thyroid microcarcinoma","volume":"56","author":"Punda","year":"2017","journal-title":"Acta Clin. Croat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1007\/s13277-015-4163-y","article-title":"Decreased expression of p27 is associated with malignant transformation and extrathyroidal extension in papillary thyroid carcinoma","volume":"37","author":"Do","year":"2016","journal-title":"Tumor Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1507\/endocrj.K08E-372","article-title":"Cytoplasmic localization of Jab1 and p27Kip1 might be associated with invasiveness of papillary thyroid carcinoma","volume":"56","author":"Ahn","year":"2009","journal-title":"Endocr. J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5858\/arpa.2014-0056-RA","article-title":"Application of immunohistochemistry in thyroid pathology","volume":"139","author":"Liu","year":"2015","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12020-012-9843-4","article-title":"BRAFV600E associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinoma","volume":"44","author":"Guerra","year":"2013","journal-title":"Endocrine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s12032-011-9969-x","article-title":"Prognostic value of oncoprotein expressions in thyroid papillary carcinoma","volume":"29","author":"Balta","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13000-015-0262-8","article-title":"Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential","volume":"10","author":"Saini","year":"2015","journal-title":"Diagn. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.canlet.2017.12.037","article-title":"A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer","volume":"417","author":"Lee","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1097\/01.XEJ.0000515966.38827.24","article-title":"Predictive role of leptin and cyclin D1 in papillary thyroid carcinoma: An immunohistochemical study","volume":"37","author":"Holah","year":"2017","journal-title":"Egypt J. Pathol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3325\/cmj.2008.5.643","article-title":"Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of the thyroid: Association with clinicopathological parameters","volume":"49","author":"Punda","year":"2008","journal-title":"Croat. Med. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-61985-1","article-title":"Enhanced expression of Cyclin D1 and C-myc, a prognostic factor and possible mechanism for recurrence of papillary thyroid carcinoma","volume":"10","author":"Sanjari","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"25","DOI":"10.16956\/kjes.2015.15.2.25","article-title":"Prognostic value of p53 and cyclin D1 in papillary thyroid carcinoma","volume":"15","author":"Seok","year":"2015","journal-title":"Korean J. Endocr. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Teshima, M., Tokita, K., Ryo, E., Matsumoto, F., Kondo, M., Ikegami, Y., Shinomiya, H., Otsuki, N., Hiraoka, N., and Nibu, K.-I. (2019). Clinical impact of a cytological screening system using cyclin D1 immunostaining and genomic analysis for the diagnosis of thyroid nodules. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5452-4"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"389","DOI":"10.4103\/0971-5916.159250","article-title":"Survivin: A molecular biomarker in cancer","volume":"141","author":"Jaiswal","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"ref_90","first-page":"1337","article-title":"Survivin expression is significantly linked to the dedifferentiation of thyroid carcinoma","volume":"10","author":"Ito","year":"2003","journal-title":"Oncol. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00508-014-0674-6","article-title":"Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance","volume":"127","author":"Selemetjev","year":"2014","journal-title":"Wiener Klinische Wochenschrift"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3892\/ijmm.2012.1046","article-title":"Targeting of the anti-apoptotic gene survivin in human thyroid carcinoma","volume":"30","author":"Chen","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.prp.2013.09.014","article-title":"Evaluation of survivin expression and its prognostic value in papillary thyroid carcinoma","volume":"210","author":"Selemetjev","year":"2014","journal-title":"Pathol. Res. Pr."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"15102","DOI":"10.4238\/2015.November.24.19","article-title":"Role of survivin in the pathogenesis of papillary thyroid carcinoma","volume":"14","author":"Li","year":"2015","journal-title":"Genet. Mol. Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/0973-1482.163675","article-title":"Concomitant high expression of survivin and vascular endothelial growth factor-C is strongly associated with metastatic status of lymph nodes in papillary thyroid carcinoma","volume":"14","author":"Savin","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1089\/thy.2013.0196","article-title":"The role of survivin in thyroid tumors: Differences of expression in well-differentiated, non\u2013well-differentiated, and anaplastic thyroid cancers","volume":"24","author":"Pannone","year":"2014","journal-title":"Thyroid"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1440-1827.2001.01159.x","article-title":"Overexpression of p53 protein and MDM2 in papillary carcinomas of the thyroid: Correlations with clinicopathologic features","volume":"51","author":"Horie","year":"2001","journal-title":"Pathol. Int."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.7314\/APJCP.2014.15.5.2341","article-title":"Clinicopathologic and diagnostic significance of p53 protein expression in papillary thyroid carcinoma","volume":"15","author":"Shin","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/PAT.0b013e3283486178","article-title":"BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: Evidence for multistep carcinogenesis","volume":"43","author":"Gauchotte","year":"2011","journal-title":"Pathology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/846584","article-title":"P53 and Expression of immunological markers may identify early stage thyroid tumors","volume":"2013","author":"Marcello","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1038\/modpathol.2017.75","article-title":"Molecular alterations of co-existing thyroid papillary carcinoma and anaplastic carcinoma: Identification of TERT mutation as an independent risk factor for transformation","volume":"30","author":"Oishi","year":"2017","journal-title":"Modern. Pathol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/bs.apcsb.2019.01.001","article-title":"Estrogen receptor signaling mechanisms","volume":"116","author":"Fuentes","year":"2019","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2013.10.013","article-title":"Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression","volume":"68","author":"Tafani","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev-physiol-030212-183708","article-title":"Estrogen and cancer","volume":"75","author":"Liang","year":"2013","journal-title":"Annu. Rev. Physiol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/156800908785133150","article-title":"Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer","volume":"8","author":"Chen","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.beem.2015.04.008","article-title":"Estrogen receptor alpha and beta in health and disease","volume":"29","author":"Jia","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2217\/fon.10.127","article-title":"Thyroid cancer gender disparity","volume":"6","author":"Rahbari","year":"2010","journal-title":"Futur. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1158\/1055-9965.EPI-15-0833","article-title":"The breast-thyroid cancer link: A systematic review and meta-analysis","volume":"25","author":"Nielsen","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Rajoria, S., Suriano, R., George, A., Shanmugam, A., Schantz, S.P., Geliebter, J., and Tiwari, R.K. (2011). estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3\u2032-diindolylmethane in thyroid cancer. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0015879"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1089\/thy.2009.0296","article-title":"Metastatic phenotype is regulated by estrogen in thyroid cells","volume":"20","author":"Rajoria","year":"2010","journal-title":"Thyroid"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1111\/j.1349-7006.2011.02017.x","article-title":"Overexpression of estrogen receptor-\u03b1 in human papillary thyroid carcinomas studied by laser-capture microdissection and molecular biology","volume":"102","author":"Perrone","year":"2011","journal-title":"Cancer Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/875125","article-title":"Role of estrogen in thyroid function and growth regulation","volume":"2011","author":"Santin","year":"2011","journal-title":"J. Thyroid. Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/med.20131","article-title":"Estrogen and its receptors in cancer","volume":"28","author":"Chen","year":"2008","journal-title":"Med. Res. Rev."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3892\/ol.2015.3223","article-title":"Expression of the estrogen receptor \u03b1, progesterone receptor and epidermal growth factor receptor in papillary thyroid carcinoma tissues","volume":"10","author":"Chen","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12020-014-0457-x","article-title":"ER-alpha and ER-beta expression in differentiated thyroid cancer: Relation with tumor phenotype across the TNM staging and peri-tumor inflammation","volume":"49","author":"Magri","year":"2014","journal-title":"Endocrine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1530\/ERC-11-0389","article-title":"Expression of estrogen and androgen receptors in differentiated thyroid cancer: An additional criterion to assess the patient\u2019s risk","volume":"19","author":"Magri","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1245\/s10434-017-5780-z","article-title":"Upregulation of the ESR1 gene and ESR ratio (ESR1\/ESR2) is associated with a worse prognosis in papillary thyroid carcinoma: The impact of the estrogen receptor \u03b1\/\u03b2 expression on clinical outcomes in papillary thyroid carcinoma patients","volume":"24","author":"Yi","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/thy.2012.0363","article-title":"Loss of estrogen receptor beta expression in follicular thyroid carcinoma predicts poor outcome","volume":"23","author":"Louhimo","year":"2013","journal-title":"Thyroid"},{"key":"ref_120","first-page":"203","article-title":"Diagnostic value of estrogen receptors in thyroid lesions","volume":"16","author":"Vaiman","year":"2010","journal-title":"Med. Sci. Monit."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1530\/EJE-15-0054","article-title":"Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer","volume":"173","author":"Vannucchi","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Huang, Y., Dong, W., Li, J., Zhang, H., Shan, Z., and Teng, W. (2014). Differential expression patterns and clinical significance of estrogen receptor-\u03b1 and \u03b2 in papillary thyroid carcinoma. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-383"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.surg.2017.04.031","article-title":"Estrogen receptor subtype expression and regulation is altered in papillary thyroid cancer after menopause","volume":"163","author":"Rubio","year":"2018","journal-title":"Surgery"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000452488","article-title":"Immunohistochemical expression of estrogen receptor-\u03b1 and progesterone receptor in patients with papillary thyroid cancer","volume":"5","author":"Sturniolo","year":"2016","journal-title":"Eur. Thyroid J."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1530\/JOE-13-0029","article-title":"Oestrogen action on thyroid progenitor cells: Relevant for the pathogenesis of thyroid nodules?","volume":"218","author":"Xu","year":"2013","journal-title":"J. Endocrinol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"T273","DOI":"10.1530\/ERC-14-0053","article-title":"Estrogen and its role in thyroid cancer","volume":"21","author":"Derwahl","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2184.2007.00471.x","article-title":"Oestrogen mediates the growth of human thyroid carcinoma cells via. an oestrogen receptor\u2014ERK pathway","volume":"40","author":"Zeng","year":"2007","journal-title":"Cell Prolif."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/iep.12266","article-title":"Reduced expression of oestrogen receptor-\u03b2 is associated with tumour invasion and metastasis in oestrogen receptor-\u03b1-negative human papillary thyroid carcinoma","volume":"99","author":"Dong","year":"2018","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/cen.12486","article-title":"Loss of ER\u03b2 expression in papillary thyroid carcinoma is associated with recurrence in young female","volume":"82","author":"Ahn","year":"2015","journal-title":"Clin. Endocrinol."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Bo\u017eovi\u0107, A., Mandu\u0161i\u0107, V., Todorovi\u0107, L., and Krajnovi\u0107, M. (2021). Estrogen receptor beta: The promising biomarker and potential target in metastases. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041656"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J. Clin. Inv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1172\/JCI39104C1","article-title":"The basics of epithelial-mesenchymal transition","volume":"120","author":"Kalluri","year":"2010","journal-title":"J. Clin. Inv."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40169-015-0055-4","article-title":"Epithelial mesenchymal transition: A double-edged sword","volume":"4","author":"Barriere","year":"2015","journal-title":"Clin. Transl. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1158\/0008-5472.CAN-05-0616","article-title":"Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition?","volume":"65","author":"Thompson","year":"2005","journal-title":"Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1349-7006.2009.01419.x","article-title":"Epithelial-mesenchymal transition in cancer development and its clinical significance","volume":"101","author":"Iwatsuki","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_136","first-page":"1","article-title":"Epithelial-mesenchymal transition in cancer: An overview","volume":"4","author":"Ramos","year":"2017","journal-title":"Integr. Cancer Sci. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s12020-019-02030-8","article-title":"Epithelial-to-mesenchymal transition in thyroid cancer: A comprehensive review","volume":"66","author":"Shakib","year":"2019","journal-title":"Endocrine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3892\/etm_00000071","article-title":"Dynamic changes in E-Cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer","volume":"1","author":"Jensen","year":"2010","journal-title":"Exp. Ther. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.yexcr.2017.04.006","article-title":"A central role for cadherin signaling in cancer","volume":"358","author":"Kourtidis","year":"2017","journal-title":"Exp. Cell Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/archsurg.142.8.717","article-title":"Identification of molecular markers altered during transformation of differentiated into anaplastic thyroid carcinoma","volume":"142","author":"Wiseman","year":"2007","journal-title":"Arch. Surg."},{"key":"ref_141","first-page":"560","article-title":"Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma","volume":"8","author":"Jung","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_142","first-page":"919","article-title":"The expression of CK19, vimentin and E-Cadherin in differentiated thyroid carcinomas","volume":"55","author":"Calangiu","year":"2014","journal-title":"Rom. J. Morphol. Embryol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e16187","DOI":"10.1097\/MD.0000000000016187","article-title":"E-Cadherin expression is associated with susceptibility and clinicopathological characteristics of thyroid cancer: A PRISMA-compliant meta-analysis","volume":"98","author":"Zhou","year":"2019","journal-title":"Medicine"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000329472","article-title":"Expression of caveolin-1, caveolin-2 and caveolin-3 in thyroid cancer and stroma","volume":"79","author":"Kim","year":"2012","journal-title":"Pathobiology"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s00423-010-0690-6","article-title":"Diagnostic utility of immunohistochemical panel in various thyroid pathologies","volume":"395","author":"Ozolins","year":"2010","journal-title":"Langenbeck\u2019s Arch. Surg."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"519","DOI":"10.5603\/FHC.2012.0073","article-title":"E-Cadherin expression is more associated with histopathological type of thyroid cancer than with the metastatic potential of tumors","volume":"50","author":"Sporny","year":"2012","journal-title":"Folia Histochem. Cyto."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/172460081002500106","article-title":"Assessment of biomarkers for clinical diagnosis of papillary thyroid carcinoma with distant metastasis","volume":"25","author":"Liang","year":"2010","journal-title":"Int. J. Biol. Markers"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1530\/EC-20-0268","article-title":"Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer","volume":"9","author":"Aghajani","year":"2020","journal-title":"Endocr. Connect."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1007\/s11064-004-6880-2","article-title":"Increased cell proliferation and neurogenesis in the hippocampal dentate gyrus of old GFAP\u2212\/\u2212Vim\u2212\/\u2212 Mice","volume":"29","author":"Wilhelmsson","year":"2004","journal-title":"Neurochem. Res."},{"key":"ref_150","first-page":"4357","article-title":"Differential protein expression of lymph node metastases of papillary thyroid carcinoma harboring the BRAF mutation","volume":"33","author":"Park","year":"2013","journal-title":"Anticancer. Res."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1002\/1097-0142(19921101)70:9<2326::AID-CNCR2820700919>3.0.CO;2-D","article-title":"An immunohistochemical study of epithelial membrane antigen, cytokeratin, and vimentin in papillary thyroid carcinoma. Recognition of lethal and favorable prognostic types","volume":"70","author":"Yamamoto","year":"1992","journal-title":"Cancer"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/B978-0-12-394311-8.00014-5","article-title":"Chapter fourteen cadherins and epithelial-to-mesenchymal transition","volume":"116","author":"Gheldof","year":"2013","journal-title":"Prog. Mol. Biol. Transl."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/13543784.16.4.451","article-title":"N-Cadherin as a therapeutic target in cancer","volume":"16","author":"Mariotti","year":"2007","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s13277-015-3820-5","article-title":"Co-expression and clinical utility of snail and N-Cadherin in papillary thyroid carcinoma","volume":"37","author":"Yang","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.18632\/oncotarget.14101","article-title":"N-Cadherin promotes thyroid tumorigenesis through modulating major signaling pathways","volume":"8","author":"Da","year":"2016","journal-title":"Oncotarget"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40164-020-00192-0","article-title":"CD44 as a tumor biomarker and therapeutic target","volume":"9","author":"Xu","year":"2020","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.7150\/ijbs.28235","article-title":"Nuclear CD44 mediated by importin \u03b2 participated in na\u00efve genes transcriptional regulation in C3A-iCSCs","volume":"15","author":"Su","year":"2019","journal-title":"Int. J. Biol. Sci."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"109377","DOI":"10.1016\/j.cellsig.2019.109377","article-title":"Hyaluronan-CD44 axis orchestrates cancer stem cell functions","volume":"63","author":"Skandalis","year":"2019","journal-title":"Cell. Signal."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1177\/0300060513481923","article-title":"Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma","volume":"41","author":"Wu","year":"2013","journal-title":"J. Int. Med. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2298\/AOO0301005K","article-title":"Immunohistochemical expression of CD44 in thyroid gland lesions","volume":"11","author":"Kiziridou","year":"2003","journal-title":"Arch. Oncol."},{"key":"ref_161","first-page":"343","article-title":"Clinical prognostic significance of cancer stem cell markers in patients with papillary thyroid carcinoma","volume":"19","author":"Ryu","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C","article-title":"Matrix metalloproteinases in tumour invasion and metastasis","volume":"189","author":"Curran","year":"1999","journal-title":"J. Pathol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrc745","article-title":"New functions for the matrix metalloproteinases in cancer progression","volume":"2","author":"Egeblad","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s004280000286","article-title":"Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas","volume":"438","author":"Maeta","year":"2001","journal-title":"Virchows Arch."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"128","DOI":"10.5483\/BMBRep.2003.36.1.128","article-title":"Roles of matrix metalloproteinases in tumor metastasis and angiogenesis","volume":"36","author":"Yoon","year":"2003","journal-title":"BMB Rep."},{"key":"ref_167","first-page":"2308","article-title":"Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis","volume":"17","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10735-013-9557-9","article-title":"Expression of TGF-\u03b21, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma","volume":"45","author":"Wang","year":"2013","journal-title":"J. Mol. Histol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/0300060513505485","article-title":"Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations","volume":"42","author":"Meng","year":"2014","journal-title":"J. Int. Med. Res."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12957-020-01958-w","article-title":"Role of MMP-9 in epithelial-mesenchymal transition of thyroid cancer","volume":"18","author":"Li","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Zarkesh, M., Zadeh-Vakili, A., Akbarzadeh, M., Fanaei, S.A., Hedayati, M., and Azizi, F. (2018). The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-5112-0"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/ajcp\/aqw184","article-title":"Coexpressed high levels of VEGF-C and active MMP-9 are associated with lymphatic spreading and local invasiveness of papillary thyroid carcinoma","volume":"146","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.matbio.2015.04.004","article-title":"Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature","volume":"44\u201346","author":"Deryugina","year":"2015","journal-title":"Matrix Biol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.5897\/AJPP12.919","article-title":"Expression and clinical significance of matrix metalloproteinase 9 (MMP9) papillary thyroid carcinomas","volume":"6","author":"Meng","year":"2012","journal-title":"Afr. J. Pharm. Pharmacol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1038\/s41598-017-07118-7","article-title":"Values of ultRASound features and MMP-9 of papillary thyroid carcinoma in predicting cervical lymph node metastases","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3325\/cmj.2014.55.128","article-title":"Enhanced activation of matrix metalloproteinase-9 correlates with the degree of papillary thyroid carcinoma infiltration","volume":"55","author":"Savin","year":"2014","journal-title":"Croat. Med. J."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/coa.13466","article-title":"Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer","volume":"45","author":"Bumber","year":"2020","journal-title":"Clin. Otolaryngol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"10675","DOI":"10.2147\/CMAR.S233776","article-title":"MMP-2, MMP-9, TIMP-1, and TIMP-2 in the peripheral blood of patients with differentiated thyroid carcinoma","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3760\/cma.j.issn.0366-6999.20130172","article-title":"Correlations between papillary thyroid cancer and peripheral blood levels of matrix metalloproteinase-2, matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and tissue inhibitor of metalloproteinase-2","volume":"126","author":"Zhou","year":"2013","journal-title":"Chin. Med. J."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1515\/biol-2019-0031","article-title":"Predictive significance of serum MMP-9 in papillary thyroid carcinoma","volume":"14","author":"Xu","year":"2019","journal-title":"Open Life Sci."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/jjco\/hyn065","article-title":"Clinicopathologic evaluation of immunohistochemical CD147 and MMP-2 expression in differentiated thyroid carcinoma","volume":"38","author":"Tan","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.prp.2012.06.011","article-title":"Evaluation of MMP2 and Caspase-3 expression in 107 cases of papillary thyroid carcinoma and its association with prognostic factors","volume":"209","author":"Saffar","year":"2013","journal-title":"Pathol. Res. Pr."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Shi, Y., Su, C., Hu, H., Yan, H., Li, W., Chen, G., Xu, D., Du, X., and Zhang, P. (2018). Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198896"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"0300060520917581","DOI":"10.1177\/0300060520917581","article-title":"Clinical value of matrix metalloproteinase-2 and -9 in ultRASound-guided radiofrequency ablation treatment for papillary thyroid carcinoma","volume":"48","author":"Pan","year":"2020","journal-title":"J. Int. Med. Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/10409230091169186","article-title":"Hypoxia, clonal selection, and the role of HIF-1 in tumor progression","volume":"35","author":"Semenza","year":"2008","journal-title":"Crit. Rev. Biochem. Mol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: Role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1101\/gad.14.16.1983","article-title":"HIF-1 and human disease: One highly involved factor","volume":"14","author":"Semenza","year":"2000","journal-title":"Genes Dev."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","article-title":"Hypoxia-inducible factors: Mediators of cancer progression and targets for cancer therapy","volume":"33","author":"Semenza","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-019-1097-0","article-title":"HER2 regulates HIF-2\u03b1 and drives an increased hypoxic response in breast cancer","volume":"21","author":"Jarman","year":"2019","journal-title":"Breast Cancer Res."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0008-6363(00)00281-9","article-title":"Molecular mechanisms of blood vessel growth","volume":"49","author":"Conway","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1128\/MCB.22.8.2515-2523.2002","article-title":"The response of c-Jun\/AP-1 to chronic hypoxia is hypoxia-inducible factor 1\u03b1 dependent","volume":"22","author":"Laderoute","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrc1187","article-title":"Targeting HIF-1 for cancer therapy","volume":"3","author":"Semenza","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1\u03b1 and HIF2\u03b1: Sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Keith","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12957-016-0785-9","article-title":"Expression of HIF-1\u03b1 and HIF-2\u03b1 correlates to biological and clinical significance in papillary thyroid carcinoma","volume":"14","author":"Liu","year":"2015","journal-title":"World J. Surg. Oncol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4061\/2011\/762905","article-title":"Hypoxia-inducible factor in thyroid carcinoma","volume":"2011","author":"Burrows","year":"2011","journal-title":"J. Thyroid. Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.3892\/etm.2016.3826","article-title":"Silencing of hypoxia-inducible factor-1\u03b1 promotes thyroid cancer cell apoptosis and inhibits invasion by downregulating WWP2, WWP9, VEGF and VEGFR2","volume":"12","author":"Ding","year":"2016","journal-title":"Exp. Ther. Med."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr. Rev."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1093\/cvr\/cvm094","article-title":"VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis","volume":"78","author":"Benest","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"ref_200","first-page":"409","article-title":"Immunohistochemical expression and prognostic significance of VEGF-C in well-differentiated thyroid cancer","volume":"16","author":"Ceric","year":"2020","journal-title":"Acta Endocrinol. Buchar."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s11596-017-1786-9","article-title":"Relationship between expression of vascular endothelial growth factor and cervical lymph node metastasis in papillary thyroid cancer: A meta-analysis","volume":"37","author":"Huang","year":"2017","journal-title":"Curr. Med. Sci."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.humpath.2013.04.014","article-title":"Co-regulatory potential of vascular endothelial growth factor\u2014A and vascular endothelial growth factor\u2013C in thyroid carcinoma","volume":"44","author":"Salajegheh","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2613.2007.00533.x","article-title":"Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases","volume":"88","author":"Jebreel","year":"2007","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Melaccio, A., Sgaramella, L., Pasculli, A., Di Meo, G., Gurrado, A., PRETe, F., Vacca, A., Ria, R., and Testini, M. (2021). Prognostic and therapeutic role of angiogenic microenvironment in thyroid cancer. Cancers, 13.","DOI":"10.3390\/cancers13112775"},{"key":"ref_205","first-page":"12","article-title":"Best use of the tyrosine kinase inhibitors in progressive differentiated thyroid cancer: Discussion","volume":"14","author":"Tuttle","year":"2016","journal-title":"Clin. Adv. Hematol. Oncol. H&O"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1210\/er.2019-00007","article-title":"Targeted therapy for advanced thyroid cancer: Kinase inhibitors and beyond","volume":"40","author":"Cabanillas","year":"2019","journal-title":"Endocr. Rev."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PAP.0000000000000184","article-title":"Aggressive variants of papillary thyroid carcinoma: Hobnail, tall cell, columnar, and solid","volume":"25","author":"Nath","year":"2018","journal-title":"Adv. Anat. Pathol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/CCO.0b013e32835b7c6b","article-title":"Aggressive variants of papillary thyroid cancer","volume":"25","author":"Roman","year":"2013","journal-title":"Curr. Opin. Oncol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:17:54Z","timestamp":1760167074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/10\/1131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":208,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["medicina57101131"],"URL":"https:\/\/doi.org\/10.3390\/medicina57101131","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]}}}